New drug combo shows promise for tough head and neck cancers
NCT ID NCT05252429
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests a combination of two drugs—docetaxel (a chemotherapy) and pembrolizumab (an immunotherapy)—in 27 people with head and neck cancer that has returned or spread. The goal is to see if the combo shrinks tumors and helps people live longer. Participants have not had prior chemotherapy for advanced disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
docetaxel and pembrolizumab
What this could lead to
If successful, this combination could offer a new treatment option for people with head and neck cancer that has returned or spread.
What could go wrong
This is a small, early-phase trial with only 27 participants. The combination may not work better than existing treatments and could cause side effects like low blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EFFECT OF DRUG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hokkaido University Hospital
Sapporo, Hokkaido, 0608648, Japan